SLC5A2 and kidney disorder: An overestimate of the reduction in albuminuria observed after starting an SGLT-2 inhibitor could, for example, result in a decision not to start other proven kidney disease–modifying treatments or make a patient ineligible for a treatment reserved for people with a certain level of albuminuria.